Life Science Executive Awards
Monday 16 November 2026London, UKLicensing Deal of the Year
This award celebrates the most impactful and innovative licensing agreement in the life sciences industry over the past year. It recognizes deals that have unlocked significant value, fostered collaboration, and demonstrated the potential to drive transformative advancements in the sector.
Criteria & Judging
It is open to European life science companies only.
Qualifying criteria:
- Open to licensing agreements involving a European Life Science company as a lead or key participant.
- The licensing deal must involve a specific drug, project, or group of drugs/projects.
- The deal must have been completed between 1 September 2025 and 1 August 2026.
- Eligible deals can include in-licensing or out-licensing agreements, co-development arrangements, or other licensing partnerships.
- The agreement must demonstrate clear potential for value creation and industry impact.
Judges will be paying particular attention to:
- The strategic importance and innovation of the licensing deal.
- The uniqueness or novelty of the deal terms and structure.
- The level of value creation for both parties involved in the agreement.
- The strength of the partnership and collaboration between the parties.
- The potential for the licensed asset(s) to drive significant advancements or industry transformation within the next 12 months.
